Dier Mardi
SEC CIK 1574591 · EDGAR
BoughtSold
Most active insiders at MDGL, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | FRIEDMAN PAUL A | Dir | — | $26.66M |
| 2 | Taub Rebecca | Dir | — | $21.68M |
| 3 | Sibold William John | Pres, CEO, Dir | — | $10.48M |
| 4 | BATE KENNETH | Dir | — | $8.03M |
| 5 | Levy Richard S | Dir | — | $7.36M |
| 6 | Dier Mardi | EVP, CFO | — | $3.77M |
| 7 | Huntsman Carole | Chief Commercial Off | — | $1.71M |
| 8 | Soergel David | Chief Medical Off | — | $952.0K |
| 9 | Kelley Shannon T | GC | — | $841.6K |
| 10 | Thakkar Rita | CAO | — | — |
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-06 | 2026-03-06 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Dier Mardi | EVP, CFO | S - Sale | $430.87 | -1,982 | 12.8K | -13% | -$854.0K |
| D | 2026-03-06 | 2026-03-04 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Dier Mardi | EVP, CFO | A - Grant | $0.00 | +5,215 | 14.5K | +56% | $0 |
| 2026-03-02 | 2026-03-02 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Dier Mardi | EVP, CFO | S - Sale | $427.21 | -1,183 | 9,257 | -11% | -$505.4K | |
| DM | 2025-12-03 | 2025-12-02 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Dier Mardi | EVP, CFO | S - Sale+OE | $578.34 | -4,173 | 12.7K | -25% | -$2.41M |
| D | 2025-12-03 | 2025-12-02 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Dier Mardi | EVP, CFO | M - OptEx | $251.63 | +4,173 | 14.6K | +40% | +$1.05M |
| 2025-03-12 | 2025-03-10 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Dier Mardi | SVP, CFO | S - Sale | $323.04 | -258 | 10.4K | -2% | -$83.3K | |
| D | 2025-03-07 | 2025-03-05 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Dier Mardi | SVP, CFO | A - Grant | $0.00 | +3,784 | 10.7K | +55% | $0 |
| M | 2025-03-05 | 2025-03-03 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Dier Mardi | SVP, CFO | S - Sale | $324.96 | -1,961 | 6,914 | -22% | -$637.3K |
| 2022-10-17 | 2022-10-14 | RARE | Ultragenyx Pharmaceutical Inc. | Dier Mardi | CFO, EVP | S - Sale | $40.16 | -1,629 | 66.7K | -2% | -$65.4K | |
| 2022-10-14 | 2022-10-12 | RARE | Ultragenyx Pharmaceutical Inc. | Dier Mardi | CFO, EVP | S - Sale | $38.22 | -3,484 | 68.3K | -5% | -$133.2K | |
| 2022-09-19 | 2022-09-16 | RARE | Ultragenyx Pharmaceutical Inc. | Dier Mardi | CFO, EVP | A - Grant | $0.00 | +20.0K | 71.8K | +39% | $0 | |
| DM | 2022-03-03 | 2022-03-01+ | RARE | Ultragenyx Pharmaceutical Inc. | Dier Mardi | CFO, EVP | S - Sale | $65.71 | -954 | 38.2K | -2% | -$62.7K |
| D | 2022-03-03 | 2022-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Dier Mardi | CFO, EVP | A - Grant | $0.00 | +14.0K | 52.2K | +37% | $0 |
| M | 2021-10-14 | 2021-10-12+ | RARE | Ultragenyx Pharmaceutical Inc. | Dier Mardi | CFO, EVP | S - Sale | $82.00 | -6,738 | 38.8K | -15% | -$552.5K |
Purchase Sale Sale after option exercise All abbreviations